REC 0/0559 滴眼液用于治疗成人患者的中度和重度神经营养性角膜炎
3 剂 REC 0/0559 滴眼液治疗成人患者 2 期(中度)和 3 期(重度)神经营养性角膜炎的疗效、安全性和药代动力学
A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.
研究概览
详细说明
This was a Phase 2, international, multicentre, dose-ranging, double-masked, randomised, parallel-group, vehicle-controlled study designed to evaluate 3 different doses of REC 0/0559 vs vehicle in patients with Stage 2 and Stage 3 neurotrophic keratitis (NK).
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Budapest、匈牙利
- Semmelweis University, Dept. of Ophthalmology
-
Pécs、匈牙利
- University of Pecs - Dpt of Ophthalmology
-
-
Vas County
-
Szombathely、Vas County、匈牙利、9700
- Markusovszky University Teaching Hospital
-
-
-
-
-
Cologne、德国、50924
- Uniklinik Koeln
-
Düsseldorf、德国、40225
- Hospital Eye University of Duesseldorf
-
Frankfurt、德国、60590
- Universitaetsklinikum Frankfurt
-
Homburg、德国
- Saarland University Medical Center
-
Mainz、德国、55131
- UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz
-
-
Bavaria
-
Munich、Bavaria、德国、80336
- Ludwig-Maximilians-Universitaet Muenchen LMU - Augenklinik
-
-
-
-
-
Bari、意大利、70124
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari Clinica Oculistica
-
Bologna、意大利、40138
- DIMES Universit di Bologna
-
Florence、意大利、50134
- Azienda Ospedaliero-Universitaria Careggi
-
Forlì、意大利
- Ospedali Privato
-
Genova、意大利、16132
- Azienda Ospedaliera Universitaria San Martino
-
Messina、意大利
- Azienda Ospedaliera Universitaria Policlinico Gaetano Martino
-
Milan、意大利、20157
- Ospedale Luigi Sacco
-
Roma、意大利、00133
- Fondazione PTV - Policlinico Tor Vergata
-
-
Calabria
-
Germaneto、Calabria、意大利、88100
- Università Magna Grecia di Catanzaro
-
-
-
-
-
Dijon、法国、21000
- Dijon University Hospital CHU Dijon
-
Paris、法国
- Hôpital Fondation Adolphe de Rothschild
-
Paris、法国、75014
- CHU Paris Centre - Hôpital Cochin
-
Paris、法国
- Hôpital Universitaire Necker
-
-
-
-
Florida
-
Crystal River、Florida、美国、34429-8722
- Nature Coast Clinical Research
-
Gainesville、Florida、美国、32605
- University of Florida
-
-
Maryland
-
Baltimore、Maryland、美国、21201
- University of Maryland School of Medicine UMSOM
-
-
Michigan
-
Ann Arbor、Michigan、美国、48105
- University of Michigan - Kellogg Eye Center
-
-
New York
-
New York、New York、美国、10003
- Mt. Sinai New York Eye and Ear Infirmary
-
-
North Carolina
-
Winston-Salem、North Carolina、美国、27157
- Wake Forest Baptist Medical Center
-
-
Tennessee
-
Nashville、Tennessee、美国、37215
- Toyos Clinic
-
-
Texas
-
Houston、Texas、美国、77025
- Houston Eye Associates HEA - Gramercy Location
-
-
Wisconsin
-
Madison、Wisconsin、美国、53705
- University of Wisconsin-Madison
-
-
-
-
-
Glasgow、英国、G75 8RG
- University Hospital Hairmyres
-
London、英国
- Moorfields Eye Hospital NHS Foundation Trust
-
Southampton、英国、SO16 6YD
- Southampton General Hospital
-
-
Mersey
-
Liverpool、Mersey、英国、L7 8XP
- Royal Liverpool University Hospital - St Paul's Clinical Eye Research Centre
-
-
-
-
-
Barakaldo、西班牙、48903
- Hospital de Cruces
-
Barcelona、西班牙
- Centro de Oftalmologia Barraquer
-
Barcelona、西班牙、08035
- Instituto Microcirugia Ocular IMO
-
Madrid、西班牙、28040
- Hospital Clinico San Carlos
-
Seville、西班牙
- Cartuja Vision - Centro de Servicios Oftlamologicos
-
-
Principality of Asturias
-
Oviedo、Principality of Asturias、西班牙、33012
- Instituto Oftalmologico Fernandez-Vega
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Have read, understood, and signed the informed consent form (ICF).
-
Be a male or female aged ≥18 years at the time of ICF signature.
-
Have stage 2 moderate (PED) or stage 3 severe (corneal ulcer) NK involving only 1 eye (study eye) and of at least 2 weeks duration. Patients with Stage 1 NK in the fellow eye can be enrolled.
for the study eye
-
Have no objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks before the screening visit despite use of conventional non-surgical treatment (eg, nonpreserved ocular lubricants, nonpreserved topical antibiotics, oral doxycycline, patching, serum tears, and/or therapeutic contact lenses) as determined by the investigator's or referring physician's medical record.
-
Have decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.
-
Have a BCDVA score ≤ 75 ETDRS letters in the study eye, due to NK.
Exclusion Criteria:
-
Have participated in any clinical trial with an investigational drug/device within 2 months before the Screening Visit and throughout the study duration.
-
Have a known hypersensitivity to one of the components of the study drug or procedural medications (eg, fluorescein), including to a compound chemically related to MT8
-
Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (eg, progressive or degenerative corneal or retinal conditions, lagophthalmos, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases), or that may compromise the safety of the patient.
-
Have a significant history of alcohol abuse or drug/solvent abuse
-
Be unwilling to comply with any study assessments or procedures.
-
Be a woman who is pregnant, nursing or planning a pregnancy.
-
Be a woman of childbearing potential not using a highly effective method of birth control.
-
Be a male patient who is not permanently sterile and who is not willing to use condoms during the study and for 4 weeks after the end of study treatment.
For the study eye:
-
Have any active ocular infection (bacterial, viral, fungal or protozoal) or active inflammation not related to NK in the study eye.
-
Have any other ocular disease requiring topical ocular treatment in the study eye during the course of the study treatment period, except for glaucoma if treated by preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study),
-
Receive topical ophthalmological treatments other than the study drug provided by the study Sponsor and the treatments allowed by the study protocol (eg, preservative-free artificial tears; preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study) for glaucoma; topical antibiotics; other than tetracycline).
-
Have severe blepharitis and/or severe meibomian gland disease in the study eye.
-
Have severe vision loss in the study eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment.
-
Have evidence of corneal ulceration/melting involving the posterior third of the corneal stroma, or perforation in the study eye.
-
Have a history of any ocular surgery (including laser or refractive surgical procedures) within 3 months before the Screening Visit in the study eye. An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the Stage 2 or 3 NK.
-
Have a history of corneal transplantation in the study eye, except if performed to treat NK and at least 6 months prior screening.
-
Have had prior surgical procedures for the treatment of NK (eg, tarsorrhaphy, conjunctival flap, etc.) except AMT, if at least 2 wks after the membrane has disappeared within the area of the PED or corneal ulcer (and at least 6 weeks after the procedure) in the study eye.
-
Use therapeutic contact lenses or wear contact lenses for refractive correction during the study treatment periods in the eye(s) with NK.
-
Have an anticipated need for punctal occlusion during the study treatment period. Patients with punctal occlusion or punctal plugs inserted before the study are eligible for enrolment provided that the punctal occlusion is maintained during the study.
-
Have an uncontrolled glaucoma at the Screening Visit. (Patients suffering from glaucoma requiring ophthalmic drops for topical treatment at the Screening Visit or during the study are not eligible, except if the ophthalmic drops is a preservative-free treatment administered maximum once daily as a single-agent treatment and at a stable regimen 4 weeks before screening and at the same dose during the study. Patients treated with oral intraocular pressure-lowering drugs at the Screening Visit and during the study may be enrolled if their glaucoma status is assessed as stable and controlled.
For the fellow eye
-
Have Stage 2 or 3 NK or perforation.
For any eye:
-
Have a history of ocular cancer.
-
Have had prior treatment with Oxervate™
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose 1 - 0.5 µg/day
Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID |
Eye drop solution in single dose unit.
其他名称:
Eye drop solution with no active substance in single dose unit. |
|
实验性的:Dose 2 - 2.5 µg/day
Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID |
Eye drop solution in single dose unit.
其他名称:
Eye drop solution with no active substance in single dose unit. |
|
实验性的:Dose 3 - 5 µg/day
Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID |
Eye drop solution in single dose unit.
其他名称:
Eye drop solution with no active substance in single dose unit. |
|
安慰剂比较:Vehicle
Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID |
Eye drop solution with no active substance in single dose unit. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Corneal Healing
大体时间:At week 8
|
The primary endpoint of this study is the percentage of patients achieving complete corneal healing of PED or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading centre. |
At week 8
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Visual Acuity
大体时间:At week 8
|
Percentage of patients who achieve a 5-, 10-, and 15-letter mean improvement in best corrected distance visual acuity (BCDVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Week 8 compared to baseline (in all patients and in patients with a central location of the PED or corneal ulcer, respectively). |
At week 8
|
合作者和调查者
合作者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- REC0559-B-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.